Canadian medical cannabis patients saw improvements in pain, anxiety, and depression over 6 months, but none reached clinically meaningful thresholds

Over 24 weeks, patients showed improvements in pain interference (-4.6 points), numeric pain rating (-1.19), anxiety (-2.24), depression (-2.79), and quality of life (-0.56). While all changes were statistically significant, none reached their respective minimal clinically significant thresholds. 85% of patients had a primary indication of pain.

Prospective observational multicenter study from the Canadian Medical Cannabis Real-World Evidence study. Adult patients chose from Health Canada-verified products via a national pharmacy platform with physician guidance. Validated questionnaires (PROMIS, NPRS, GAD-7, PHQ-9, EQ-5D-3L) administered at weeks 0, 6, 12, and 24. Analyzed per-protocol and intention-to-treat.

This is a rare long-term observational study of physician-authorized medical cannabis with validated outcome measures. The gap between statistical significance and clinical significance raises important questions about how meaningful the improvements actually are for patients.

This finding is nuanced: medical cannabis is associated with measurable improvements, but those improvements may not be large enough to feel meaningfully different to patients. This is a common challenge in pain medicine and warrants honest discussion in the medical cannabis debate.

No control group or randomization. Small sample sizes at 24 weeks due to dropout. Cannot separate cannabis effects from placebo, natural disease course, or concurrent treatments. Product heterogeneity across patients.